These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 9096666)
1. Induction of graft vs. tumor effect in a murine model of mammary adenocarcinoma. Morecki S; Moshel Y; Gelfend Y; Pugatsch T; Slavin S Int J Cancer; 1997 Mar; 71(1):59-63. PubMed ID: 9096666 [TBL] [Abstract][Full Text] [Related]
2. Cell therapy with preimmunized effector cells mismatched for minor histocompatible antigens in the treatment of a murine mammary carcinoma. Morecki S; Yacovlev E; Gelfand Y; Uzi I; Slavin S J Immunother; 2001; 24(2):114-21. PubMed ID: 11265768 [TBL] [Abstract][Full Text] [Related]
3. Allogeneic cell therapy for a murine mammary carcinoma. Morecki S; Yacovlev E; Diab A; Slavin S Cancer Res; 1998 Sep; 58(17):3891-5. PubMed ID: 9731499 [TBL] [Abstract][Full Text] [Related]
4. Involvement of the K and I regions of the H-2 complex in resistance to hemopoietic allografts. Drizlikh G; Schmidt-Sole J; Yankelevich B J Exp Med; 1984 Apr; 159(4):1070-82. PubMed ID: 6142918 [TBL] [Abstract][Full Text] [Related]
5. Allogeneic versus syngeneic killer splenocytes as effector cells for the induction of graft-versus-tumor effect. Morecki S; Yacovlev E; Gelfand Y; Vilensky A; Slavin S Biol Blood Marrow Transplant; 2004 Jan; 10(1):40-8. PubMed ID: 14752778 [TBL] [Abstract][Full Text] [Related]
6. Requirement for B cells in T cell priming to minor histocompatibility antigens and development of graft-versus-host disease. Schultz KR; Paquet J; Bader S; HayGlass KT Bone Marrow Transplant; 1995 Aug; 16(2):289-95. PubMed ID: 7581150 [TBL] [Abstract][Full Text] [Related]
7. Inhibition of natural killer cell-mediated bone marrow graft rejection by allogeneic major histocompatibility complex class I, but not class II molecules. Ohlén C; Höglund P; Sentman CL; Carbone E; Ljunggren HG; Koller B; Kärre K Eur J Immunol; 1995 May; 25(5):1286-91. PubMed ID: 7774631 [TBL] [Abstract][Full Text] [Related]
8. Creation of chimeric hearts: a tool for testing the "passenger leukocyte" hypothesis. Eiref SD; Zhang W; Popma SH; Shah LJ; Moore JS; Rosengard BR Ann Thorac Surg; 1997 Sep; 64(3):628-33. PubMed ID: 9307449 [TBL] [Abstract][Full Text] [Related]
9. Cell Therapy With Preimmunized Effector Cells Mismatched for Minor Histocompatible Antigens in the Treatment of a Murine Mammary Carcinoma. Morecki S; Yacovlev E; Gelfand Y; Uzi I; Slavin S J Immunother (1991); 2001 Mar; 24(2):114-121. PubMed ID: 11449067 [TBL] [Abstract][Full Text] [Related]
10. Differences in non-MHC alloantigens promote tissue rejection but fail to mediate allogeneic co-operation and autoimmunity in mice neonatally injected with semi-allogeneic F1 B cells. Ramos A; Merino R; Merino J Immunology; 1994 Jun; 82(2):287-93. PubMed ID: 7927500 [TBL] [Abstract][Full Text] [Related]
11. Transplantation of autoimmune potential. I. Development of antinuclear antibodies in H-2 histocompatible recipients of bone marrow from New Zealand Black mice. Morton JI; Siegel BV Proc Natl Acad Sci U S A; 1974 Jun; 71(6):2162-5. PubMed ID: 4601580 [TBL] [Abstract][Full Text] [Related]
12. Differential requirement for a cellular type-1 immune response in tumor-associated versus alloantigen-targeted GvT effects. Stelljes M; Specht C; Albring J; Volkmann S; Schlösser V; Pauels HG; Poremba C; Bisping G; Opitz C; Scheffold C; Silling G; Kiehl M; Berdel WE; Kienast J Transplantation; 2007 Feb; 83(3):314-22. PubMed ID: 17297406 [TBL] [Abstract][Full Text] [Related]
13. Spontaneous and IL-2-induced anti-leukemic and anti-host effects against tumor- and host-specific alloantigens. Cohen P; Vourka-Karussis U; Weiss L; Slavin S J Immunol; 1993 Nov; 151(9):4803-10. PubMed ID: 8409438 [TBL] [Abstract][Full Text] [Related]
14. Do donor cells function as veto cells in the induction and maintenance of tolerance across an MHC disparity in mixed lymphoid radiation chimeras? Pierce GE; Watts LM Transplantation; 1993 Apr; 55(4):882-7. PubMed ID: 8475564 [TBL] [Abstract][Full Text] [Related]
15. A nonlethal conditioning approach to achieve durable multilineage mixed chimerism and tolerance across major, minor, and hematopoietic histocompatibility barriers. Colson YL; Wren SM; Schuchert MJ; Patrene KD; Johnson PC; Boggs SS; Ildstad ST J Immunol; 1995 Nov; 155(9):4179-88. PubMed ID: 7594573 [TBL] [Abstract][Full Text] [Related]
16. T lymphocyte responses to multiple minor histocompatibility antigens generate both self-major histocompatibility complex-restricted and cross-reactive cytotoxic T lymphocytes. Tremblay N; Fontaine P; Perreault C Transplantation; 1994 Jul; 58(1):59-67. PubMed ID: 8036709 [TBL] [Abstract][Full Text] [Related]
17. Non-MHC genes determine the development of lupus nephritis in H-2 identical mouse strains. Sutmuller M; Ekstijn GL; Ouellette S; De Heer E; Bruijn JA Clin Exp Immunol; 1996 Nov; 106(2):265-72. PubMed ID: 8918572 [TBL] [Abstract][Full Text] [Related]
18. Newborn blood used as a source of donor cells in a murine model of transplantation across non-MHC antigens. de la Selle V; Bruley-Rosset M Ann N Y Acad Sci; 1995 Dec; 770():351-60. PubMed ID: 8597373 [TBL] [Abstract][Full Text] [Related]
19. In situ augmentation of class I major histocompatibility antigen expression on immunogenic variants of a spontaneous murine mammary carcinoma. Elliott BE; Carlow DA; Ivimey L; Arnold M; Hampton N; Bosman P Cancer Res; 1987 Sep; 47(18):4915-23. PubMed ID: 2441856 [TBL] [Abstract][Full Text] [Related]
20. Keratinocytes synthesize Ia antigen in acute cutaneous graft-vs-host disease. Breathnach SM; Katz SI J Immunol; 1983 Dec; 131(6):2741-5. PubMed ID: 6417231 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]